URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Jonathan Elliott Dickinson net worth and biography

Jonathan Dickinson Biography and Net Worth

EVP of Incyte

Jonathan Dickinson joined Incyte as Senior Vice President and General Manager, Europe in June 2016. Mr. Dickinson joined Incyte from ARIAD Pharmaceuticals (Europe) Sàrl where he most recently held the position of Senior Vice President and General Manager, Europe. Prior to ARIAD, Mr. Dickinson served as European oncology brand lead at Bristol-Myers Squibb and before that, he held several key leadership positions, including lifecycle leader, during his 13-year tenure at Hoffmann-La Roche. At Roche, he had assignments both in the United States and Switzerland that included leadership roles for Roche’s three leading oncology medicines. Mr. Dickinson began his career at Novartis, where he held commercial roles in its oncology and endocrinology businesses, including medical sales, product manager and business director in the United Kingdom. Mr. Dickinson received his Bachelor of Science degree in Genetics and his MBA degree from the University of Nottingham.

What is Jonathan Elliott Dickinson's net worth?: The estimated net worth of Jonathan Elliott Dickinson is at least $2.54 million as of September 12th, 2024. Mr. Dickinson owns 36,390 shares of Incyte stock worth more than $2,544,025 as of December 25th. This net worth approximation does not reflect any other investments that Mr. Dickinson may own. Learn More about Jonathan Elliott Dickinson's net worth.
How do I contact Jonathan Elliott Dickinson?: The corporate mailing address for Mr. Dickinson and other Incyte executives is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. Incyte can also be reached via phone at (302) 498-6700 and via email at [email protected]. Learn More on Jonathan Elliott Dickinson's contact information.
Has Jonathan Elliott Dickinson been buying or selling shares of Incyte?: Jonathan Elliott Dickinson has not been actively trading shares of Incyte during the past quarter. Most recently, Jonathan Elliott Dickinson sold 8,450 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $62.36, for a transaction totalling $526,942.00. Following the completion of the sale, the executive vice president now directly owns 36,390 shares of the company's stock, valued at $2,269,280.40. Learn More on Jonathan Elliott Dickinson's trading history.
Who are Incyte's active insiders?: Incyte's insider roster includes Dashyant Dhanak (EVP), Jonathan Dickinson (EVP), Wendy Dixon (Director), Barry Flannelly (EVP), Herve Hoppenot (CEO & Chairman), Vijay Iyengar (EVP), Michael Morrissey (EVP), Maria Pasquale (EVP), Steven Stein (EVP), Paula Swain (EVP), Thomas Tray (Insider), and Wenquing Yao (EVP). Learn More on Incyte's active insiders.
Are insiders buying or selling shares of Incyte?: During the last twelve months, insiders at the biopharmaceutical company sold shares 12 times. They sold a total of 65,984 shares worth more than $4,322,270.69. The most recent insider tranaction occured on December, 16th when insider Thomas Tray sold 650 shares worth more than $45,051.50. Insiders at Incyte own 17.6% of the company. Learn More about insider trades at Incyte.
Information on this page was last updated on 12/16/2024.

Jonathan Elliott Dickinson Insider Trading History at Incyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/12/2024	Sell	8,450	$62.36	$526,942.00	36,390
1/31/2022	Sell	7,375	$74.19	$547,151.25
6/22/2020	Sell	9,000	$105.31	$947,790.00	36,461

Jonathan Elliott Dickinson Buying and Selling Activity at Incyte

Incyte Company Overview

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $69.91

$68.92

$70.10

50 Day Range

MA: $72.58

$65.07

$83.38

2 Week Range

Now: $69.91

$50.35

$83.95

Volume

395,905 shs

Average Volume

2,341,950 shs

Market Capitalization

$13.47 billion

P/E Ratio

499.39

Dividend Yield

N/A

Beta

0.69

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now